FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2021/11/038268 [Registered on: 25/11/2021] Trial Registered Prospectively
Last Modified On: 07/12/2021
Post Graduate Thesis  No 
Type of Trial  Interventional 
Type of Study   Drug
Surgical/Anesthesia 
Study Design  Randomized, Parallel Group Trial 
Public Title of Study   To compare the results of two treatment protocol (standard treatment plus vitamin c, thiamine and hydrocortisone versus standard treatment plus hydrocortisone) used in surgical patients with septic shock (a/k/a infection in the body presenting with low blood pressure). 
Scientific Title of Study   Metabolic resuscitation using early administration of ascorbic acid, thiamine and hydrocortisone in perioperative management of surgical patients with septic shock: A Randomized Controlled trial 
Trial Acronym   
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Manjunath Maruti Pol 
Designation  Additional Professor Surgery 
Affiliation  All India Institute of Medical Sciences New Delhi 
Address  Department of Surgical Disciplines, CMET, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi
Department of Surgical Disciplines, CMET, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi
South
DELHI
110029
India 
Phone  09990187137  
Fax    
Email  manjunath.pol@gmail.com  
 
Details of Contact Person
Scientific Query
 
Name  Manjunath Maruti Pol 
Designation  Additional Professor Surgery 
Affiliation  All India Institute of Medical Sciences New Delhi 
Address  Department of Surgical Disciplines, CMET, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi
Department of Surgical Disciplines, CMET, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi
South
DELHI
110029
India 
Phone  09990187137  
Fax    
Email  manjunath.pol@gmail.com  
 
Details of Contact Person
Public Query
 
Name  Manjunath Maruti Pol 
Designation  Additional Professor Surgery 
Affiliation  All India Institute of Medical Sciences New Delhi 
Address  Department of Surgical Disciplines, CMET, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi
Department of Surgical Disciplines, CMET, All India Institute of Medical Sciences (AIIMS), Ansari Nagar, New Delhi
South
DELHI
110029
India 
Phone  09990187137  
Fax    
Email  manjunath.pol@gmail.com  
 
Source of Monetary or Material Support  
AIIMS New Delhi 
 
Primary Sponsor  
Name  AIIMS NEW DELHI 
Address  Department of Surgical Disciplines. CMET, Second floor teachingblock AIIMS main building. All India Institute of Medical SciencesAIIMS Ansari Nagar New Delhi South DELHI 
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Manjunath Maruti Pol  AIIMS Delhi  Department of Surgical Disciplines CMET teaching block AIIMS main building All India Institute of Medical Sciences AIIMS Ansari Nagar New Delhi South DELHI
South
DELHI 
09990187137

manjunath.pol@gmail.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
AIIMS Institute Ethics Committee  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition: A419||Sepsis, unspecified organism,  
 
Intervention / Comparator Agent  
Type  Name  Details 
Intervention  Group A  Standard treatment plus Hydrocortisone 100 mg IV bolus then 50 mg IV every 6th hourly for 10 days Ascorbic acid 1.5 gm. q 6th hourly for 10 days Thiamine 200 mg q 12th hourly for 10 days  
Comparator Agent  Group B  Standard treatment plus Hydrocortisone 100 mg IV bolus then 50 mg IV every 6th hourly for 10 days  
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  70.00 Year(s)
Gender  Both 
Details  1. Perioperative septic shock: peritonitis due to hollow viscus perforation, ruptured solid organ abscess, pyoperitoneum, intestinal obstruction.
2. Controlled source of infection: Post-intervention (surgical or non-surgical) control of source of infection
3. 18 to 70 years, both gender
4. Ready to participate in the study

 
 
ExclusionCriteria 
Details  1. Age < 18 years and > 70 years
2. Refusal to consent and DNR orders (patient or patients family do not consent for the resuscitation and study)
3. Septic shock for > 24 hours
4. Failure to administer intervention drugs within 6 hours of presentation of septic shock
5. Proven active COVID-19 infection, HIV infection, known immunodeficiency diseases
6. Allergy to either of the intervention drugs (allergy to ascorbic acid or thiamine or hydrocortisone)
7. Uncontrollable source of infection e.g., Unresectable dead bowel,
8. Recurrent, unresectable or metastatic cancer
9. Patient on antifungal infection for systemic fungal infection
10. Imminent death or Inevitable deaths: metastatic cancer or haematological malignancy, more than four failed organs at entry (or multiorgan dysfunction syndrome), APACHE II score > 30 at presentation, granulocytopenia leucocyte count < 500cells/ml and/or thrombocytopenia< 30000 cells/ml)
11. Alternate diagnosis causing shock e.g., myocardial infarction and severe congestive cardiac failure (NYHA class IV), pulmonary embolism, Child Pugh class C liver disease, patients on immunosuppressant’s, chemotherapy / radiotherapy within 30 days prior to sepsis, haemorrhagic shock or GCS-3.
12. Pregnancy or breastfeeding
13. G6PD deficiency
14. Patients already on hydrocortisone, ascorbic acid and thiamine for reasons other than septic shock
 
 
Method of Generating Random Sequence   Computer generated randomization 
Method of Concealment   Sequentially numbered, sealed, opaque envelopes 
Blinding/Masking   Open Label 
Primary Outcome  
Outcome  TimePoints 
1. Inotrope free survival (Cessation of vasopressor)  Hours to 10 days 
 
Secondary Outcome  
Outcome  TimePoints 
1. Reduction in Sequential Organ Failure Assessment (SOFA) Score
2. Duration of hospital stay
3. Duration of ICU stay
4. Mortality
 
1. 0 to 24
2. 1 to 30 days
3. 1 to 30 days
4. 1 to 30 days 
 
Target Sample Size   Total Sample Size="60"
Sample Size from India="60" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   29/11/2021 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="2"
Months="0"
Days="0" 
Recruitment Status of Trial (Global)
Modification(s)  
Not Applicable 
Recruitment Status of Trial (India)  Open to Recruitment 
Publication Details   NIL 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  

Background and rationale of the study:

·      Sepsis is a life threatening clinical syndrome caused by dysregulated host immune response to infection leading to constellation of physiologic and biochemical abnormalities. Thus, sepsis involves persistent inflammation, immunosuppression and catabolic syndrome.

·      Our observation suggests that there was > 50% mortality witnessed during perioperative management of surgical patients with septic shock. As there is no study comparing the two treatment protocols in perioperative management of surgical patients with septic shock, an intervention to look for the difference and enhance the outcome in surgical patients with septic shock is warranted.

·      From the available literature, there have been no reports of suspected, unexpected, or serious adverse reactions to dose and frequency of intervention drugs to be used in this study.

·      The role of cocktail of Vit-C and hydrocortisone is under investigation. It has been used in cases of medical sepsis.

·      Hypothesis behind use of Vit-C and thiamine in septic shock: The concept that inotrope induced vasoconstriction and lactic acidosis has come under criticism. It is postulated that tissue hypoxia is not the actual cause for excess production of lactic acid, but when excess amount of pyruvate is generated it gets bypassed (from Krebs cycle) to form lactic acid due to lack of vitamins. Secondly, due to infection the receptor (SVCT2) needed for transport of Vit- C is decreased, and the corticosteroids receptor is oxidized by the inflammatory mediators. Therefore, it is observed that giving hydrocortisone increases expression of SVCT2, and Vit-C helps to reverse oxidized corticosteroids receptors.

·      There is no study in the English literature comparing the two treatment protocol [standard treatment plus cocktail of vitamin and hydrocortisone versus standard treatment plus hydrocortisone] in patients with surgical sepsis. However, there are a few articles published in medical journals (Marik PE et al. Chest. 2017 and Fujii T et. Al JAMA. 2020) that involved majority of patients with pulmonary sepsis. [1, 2] In a study published by Marik PE et al. Chest. 2017 it was observed that early administrations of higher doses of vitamin-c and thiamine along with corticosteroids in pulmonary sepsis prevented progression of disease and reduced mortality. On contrary, the vitamins trial (Fujii T et. Al JAMA. 2020) did not reflect similar results that could be due to non-adherence to sepsis protocol. Variations in their outcome could have resulted because of differences in their study design and execution. Hence, there is an on-going debate about role of metabolic resuscitation in medical sepsis.

1. 

     1. Marik PE, Khangoora V, Rivera R, et al. Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Severe Sepsis and Septic Shock: A Retrospective Before-After Study. Chest. 2017; 151(6): 1229-1238.

2. 2.Fujii T, Luethi N, Young PJ, et al. Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial. JAMA. 2020; 323(5): 423-431.


 
Close